0001144204-17-063223.txt : 20171211 0001144204-17-063223.hdr.sgml : 20171211 20171211210135 ACCESSION NUMBER: 0001144204-17-063223 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171127 FILED AS OF DATE: 20171211 DATE AS OF CHANGE: 20171211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weyer Christian CENTRAL INDEX KEY: 0001493811 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 171250735 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 450 W. 15TH STREET STREET 2: SUITE 505 CITY: NEW YORK STATE: NY ZIP: 10011 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 450 W. 15TH STREET STREET 2: SUITE 505 CITY: New York STATE: NY ZIP: 10011 4 1 tv480792_4.xml OWNERSHIP DOCUMENT X0306 4 2017-11-27 0 0001270073 INTERCEPT PHARMACEUTICALS INC ICPT 0001493811 Weyer Christian C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, FLOOR 37 NEW YORK NY 10001 0 1 0 0 EVP Research and Development Common Stock 2017-11-27 4 A 0 16500 0 A 16500 D Option to Purchase Common Stock 59.12 2017-11-27 4 A 0 25000 0 A 2027-11-27 Common Stock 25000 25000 D 25% of the shares of restricted stock will vest on November 27, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through November 27, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan. 25% of the shares of common stock underlying this option will vest on November 27, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through November 27, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. /s/ Mark Pruzanski, as attorney-in-fact 2017-12-11